Remogliflozin etabonate

Remogliflozin etabonate (pronunciation: re-mo-gli-flo-zin e-ta-bo-nate) is an antidiabetic drug used in the treatment of type 2 diabetes. It belongs to the class of drugs known as SGLT2 inhibitors.

Etymology

The name "Remogliflozin" is derived from the chemical structure of the drug, which is a glucose analog. The suffix "-flozin" is common to all drugs in the SGLT2 inhibitor class. The term "etabonate" refers to the ester formed with etabonic acid to improve the drug's pharmacokinetic properties.

Pharmacology

Remogliflozin etabonate works by inhibiting the sodium-glucose transport proteins (SGLT2) in the kidneys. This results in the reduction of reabsorption of glucose by the kidneys, leading to the excretion of glucose in urine and thus lowering blood glucose levels.

Clinical Use

Remogliflozin etabonate is used in the management of type 2 diabetes, often in combination with diet and exercise. It may be used alone or in combination with other antidiabetic drugs.

Side Effects

Common side effects of Remogliflozin etabonate include urinary tract infections, increased urination, and yeast infections. More serious side effects may include kidney problems, low blood sugar, and a rare but serious condition known as ketoacidosis.

Related Terms

• Type 2 diabetes
• SGLT2 inhibitors
• Sodium-glucose transport proteins
• Ketoacidosis

External links

• Medical encyclopedia article on Remogliflozin etabonate
• Wikipedia's article - Remogliflozin etabonate

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski